|
94 Companies |
|
165 Products |
|
165 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
1453 News |
|
| «12...7891011121314151617...2930» |
- || Elelyso (taliglucerase alfa) / Pfizer
Trial completion, Enrollment change: A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease (clinicaltrials.gov) - Sep 11, 2014
P3, N=19, Completed, Sponsor: Protalix
Active, not recruiting --> Completed | N=25 --> 19
- || Elelyso (taliglucerase alfa) / Pfizer
Trial completion, Trial primary completion date: A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease (clinicaltrials.gov) - Sep 11, 2014
P3, N=15, Completed, Sponsor: Protalix
Active, not recruiting --> Completed | N=25 --> 19 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014
- Clinical: SFLABPASTA: Healthy Effects of an Innovative Probiotic Pasta (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=40, Recruiting, Sponsor: University of Parma
- tropicamide / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients (clinicaltrials.gov) - Sep 8, 2014
P=N/A, N=8, Recruiting, Sponsor: Université de Montréal
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 | Trial primary completion date: May 2016 --> Aug 2016
- Trial primary completion date: Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression (clinicaltrials.gov) - Sep 8, 2014
P1, N=300, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 | Trial primary completion date: May 2016 --> Aug 2016 Trial primary completion date: Aug 2014 --> Aug 2016
- ||||| Praluent (alirocumab) / Sanofi, Regeneron
Enrollment closed: Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN) (clinicaltrials.gov) - Sep 8, 2014
P3, N=216, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Aug 2014 --> Aug 2016 Recruiting --> Active, not recruiting
- Cerdelga (eliglustat tartrate) / Sanofi
Trial primary completion date: A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients (clinicaltrials.gov) - Sep 4, 2014
P2, N=26, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2008 --> Aug 2009
- PF-06427878 / Pfizer
Enrollment open: A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects (clinicaltrials.gov) - Aug 28, 2014
P1, N=24, Recruiting, Sponsor: Pfizer
Trial primary completion date: Sep 2008 --> Aug 2009 Not yet recruiting --> Recruiting
- ||| rosuvastatin / Generic mfg.
New P3 trial: HYDRA: A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Aug 27, 2014
P3, N=25, Not yet recruiting, Sponsor: AstraZeneca
- ||||| bococizumab (RN316) / Pfizer
Enrollment change, Trial primary completion date: SPIRE-LL: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Aug 26, 2014
P3, N=690, Not yet recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=939 --> 690 | Trial primary completion date: Mar 2016 --> Jul 2016
- Enrollment closed, Trial primary completion date: Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans (clinicaltrials.gov) - Aug 22, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Chandan K Sen
N=939 --> 690 | Trial primary completion date: Mar 2016 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Apr 2015
- |||| CaPre (omega-3 phospholipid) / Acasti Pharma
Trial completion: TRIal For Efficacy of Capre on hyperTriglyceridemiA (clinicaltrials.gov) - Aug 22, 2014
P2, N=387, Completed, Sponsor: Acasti Pharma Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Apr 2015 Recruiting --> Completed
- || Enrollment change: REMAINS: Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204) (clinicaltrials.gov) - Aug 22, 2014
P=N/A, N=635, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=482 --> 635
- Clinical: Lipidown: Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=75, Recruiting, Sponsor: Nestlé
- |||| obicetrapib (TA-8995) / NewAmsterdam Pharma
Trial completion, Combination therapy: TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP) (clinicaltrials.gov) - Aug 21, 2014
P2, N=364, Completed, Sponsor: Xention Ltd
N=482 --> 635 Active, not recruiting --> Completed
- ||||||| Praluent (alirocumab) / Sanofi, Regeneron
Trial completion, Combination therapy: Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I) (clinicaltrials.gov) - Aug 21, 2014
P3, N=347, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Characterization of Dyslipidemia in Adolescent Obesity (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=50, Completed, Sponsor: Health Diagnostic Laboratory, Inc.
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Jun 2014
- || simvastatin / Generic mfg., valsartan / Generic mfg.
Phase classification: A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia (clinicaltrials.gov) - Aug 19, 2014
P3, N=871, Completed, Sponsor: Novartis
Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Jun 2014 Phase classification: P4 --> P3
- atorvastatin / Generic mfg., rosuvastatin / Generic mfg.
Trial completion: LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=1000, Completed, Sponsor: Listen Trial Group
Phase classification: P4 --> P3 Active, not recruiting --> Completed
- || Enrollment closed, Trial primary completion date: Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: Zeltiq Aesthetics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2015
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Trial primary completion date: ODYSSEY FH I: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (clinicaltrials.gov) - Aug 15, 2014
P3, N=471, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Dec 2014 --> Oct 2013
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Trial primary completion date: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH) (clinicaltrials.gov) - Aug 15, 2014
P3, N=105, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Dec 2014 --> Oct 2013 Trial primary completion date: Jan 2015 --> Nov 2013
- || New P3 trial: Supplementation of Dual Probiotic Strains Reduced Fasting Triglyceride and Enhanced Apolipoprotein A-V Levels (clinicaltrials.gov) - Aug 15, 2014
P3, N=128, Completed, Sponsor: Yonsei University
- New P2 trial: Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile (clinicaltrials.gov) - Aug 15, 2014
P2, N=10, Completed, Sponsor: Micropharma Limited
- ezetimibe / Generic mfg., colestipol / Generic mfg.
Trial completion, Enrollment change: A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction (clinicaltrials.gov) - Aug 12, 2014
P4, N=30, Completed, Sponsor: Tuscaloosa Research & Education Advancement Corporation
Trial primary completion date: Jan 2015 --> Nov 2013 Recruiting --> Completed | N=90 --> 30
- Targretin oral (bexarotene oral) / ReXceptor
Trial primary completion date: TgBEX: Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma (clinicaltrials.gov) - Aug 11, 2014
P4, N=15, Recruiting, Sponsor: Rennes University Hospital
Recruiting --> Completed | N=90 --> 30 Trial primary completion date: May 2014 --> Dec 2014
- | icosabutate (NST-4016) / Abbott, NorthSea Therap
Trial termination: Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia (clinicaltrials.gov) - Aug 7, 2014
P2, N=113, Terminated, Sponsor: Pronova BioPharma
Trial primary completion date: May 2014 --> Dec 2014 Recruiting --> Terminated
- ||| omega-3 ethylester concentrate / Generic mfg.
Enrollment closed, Trial primary completion date, Head-to-Head: The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels (clinicaltrials.gov) - Aug 7, 2014
P4, N=206, Active, not recruiting, Sponsor: Enzymotec
Recruiting --> Terminated Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Nov 2014
- |||| icosabutate (NST-4016) / Abbott, NorthSea Therap
Trial completion: The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects (clinicaltrials.gov) - Aug 7, 2014
P2, N=87, Completed, Sponsor: Pronova BioPharma
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Nov 2014 Active, not recruiting --> Completed
- ||||| bococizumab (RN316) / Pfizer
Trial initiation date: SPIRE-LL: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Aug 6, 2014
P3, N=939, Not yet recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Initiation date: May 2014 --> Aug 2014
- | PF-06427878 / Pfizer
New P1 trial: A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects (clinicaltrials.gov) - Aug 5, 2014
P1, N=24, Not yet recruiting, Sponsor: Pfizer
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
New P3 trial: EBBINGHAUS: Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (clinicaltrials.gov) - Aug 4, 2014
P3, N=4000, Not yet recruiting, Sponsor: Amgen
- Olbetam (acipimox) / Pfizer
Enrollment closed: Effects of Acipimox on Mitochondrial Function in Obesity (clinicaltrials.gov) - Aug 4, 2014
P2, N=40, Active, not recruiting, Sponsor: Massachusetts General Hospital
Initiation date: May 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- Clinical: Bergamot and Cardio-Metabolic Risk Factors (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=160, Recruiting, Sponsor: University of Palermo
- |||||||||| Rosuzet (rosuvastatin/ezetimibe) / Hanmi, Merck (MSD)
New P3 trial: Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia (clinicaltrials.gov) - Aug 1, 2014
P3, N=400, Recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
- | Trial completion, Enrollment change: A Multiple Dose Study Of PF-06678552 In Healthy Subjects (clinicaltrials.gov) - Aug 1, 2014
P1, N=38, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Completed | N=74 --> 38
- ||| Trial completion: Effects Of Consumption Of A Highly Mineralized Sodium Bicarbonated Water On Blood Lipid Profile (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=162, Completed, Sponsor: Neptune
Recruiting --> Completed | N=74 --> 38 Recruiting --> Completed
- |||||| bococizumab (RN316) / Pfizer
Enrollment open: SPIRE-SI: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (clinicaltrials.gov) - Jul 26, 2014
P3, N=300, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: A Trial to Evaluate the Efficacy of AB-Life Probiotic Product on LDL-Cholesterol Reduction in Moderate Hypercholesterolemia (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=104, Not yet recruiting, Sponsor: AB Biotics, SA
- |||| Trial completion, Trial primary completion date: Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia (clinicaltrials.gov) - Jul 23, 2014
P2, N=116, Completed, Sponsor: Beijing Peking University WBL Biotech Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Aug 2012 --> Dec 2012
- ||| fluvastatin / Generic mfg.
Enrollment change: Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (clinicaltrials.gov) - Jul 23, 2014
P4, N=436, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Aug 2012 --> Dec 2012 N=242 --> 436
- ||||| Praluent (alirocumab) / Sanofi, Regeneron
Enrollment closed: Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II) (clinicaltrials.gov) - Jul 23, 2014
P3, N=200, Active, not recruiting, Sponsor: Sanofi
N=242 --> 436 Recruiting --> Active, not recruiting
- Trial completion: IPOP: Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=32, Completed, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: DRS: The Metabolic Effects of Consuming Sugar-Sweetened Beverages for Two Weeks (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=214, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jul 2013 --> Jan 2014
- Myalept (metreleptin) / Novelion
Enrollment closed, Trial primary completion date: An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy (clinicaltrials.gov) - Jul 21, 2014
P=N/A, N=41, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | Trial primary completion date: Jul 2013 --> Jan 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Oct 2014
- Trial primary completion date: Translating a Heart Disease Lifestyle Intervention Into the Community (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=60, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Oct 2014 Trial primary completion date: May 2014 --> Dec 2013
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
New P3 trial, Combination therapy: FLOREY: Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (clinicaltrials.gov) - Jul 15, 2014
P3, N=80, Recruiting, Sponsor: Amgen
- | Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
New P1 trial: ECLIPSEIV: An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova (clinicaltrials.gov) - Jul 14, 2014
P1, N=24, Not yet recruiting, Sponsor: Omthera Pharmaceuticals, Inc
- || New P3 trial: Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels (clinicaltrials.gov) - Jul 12, 2014
P3, N=210, Recruiting, Sponsor: Joe Fenn
- | metformin/rosuvastatin (JLP1310) / Jeil
New P1 trial: Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin (clinicaltrials.gov) - Jul 12, 2014
P1, N=24, Not yet recruiting, Sponsor: Jeil Pharmaceutical Co., Ltd.